Testing the safety and effectiveness of a new cream in men with seborrheic dermatitis of the face and chest
Not Applicable
Completed
- Conditions
- Seborrheic dermatitisSkin and Connective Tissue Diseases
- Registration Number
- ISRCTN77871064
- Lead Sponsor
- ISDIN S.A.
- Brief Summary
2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31705438 (added 11/11/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
1. Males in otherwise good health
2. Aged 21-65 years at time of enrollment
3. Mild to moderate visible SD on face and chest area
Exclusion Criteria
1. Acute or chronic disease or medical condition that could put participant at risk in the opinion of the Principal Investigator or compromise study outcomes
2. History of allergic reactions, skin sensitization and/or known allergies to cosmetic ingredients, toiletries, sunscreens, etc.
3. Immunocompromised
4. Taking other medications (oral or topical) that could interfere with the interpretation of the results
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Severity of seborrheic dermatitis assessed using a scoring index (SI) evaluating erythema, desquamation, itching and irritation at baseline and after 7 and 14 days of treatment<br> 2. Seborrheic dermatitis severity assessed using the Investigator's Global Assessment Score (IGA) at baseline and after 7 and 14 days of treatment<br>
- Secondary Outcome Measures
Name Time Method